You are here: Industry Insights > Ocrevus

News List

Biogen to spend $700M to build its stake to 49.9% in biosims joint venture with Samsung fiercepharma
July 02, 2018
After Biogen reported first-quarter results back in April, CFO Jeff Cappello said the company would get further involved in an "attractive value creation" opportunity: its biosimiliars joint venture with Samsung BioLogics. Now, the drugmaker is disclosing
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study fiercevaccines
June 26, 2018
Roche’s multiple sclerosis newcomer Ocrevus was approved by the FDA last March bearing a warning about immunization.
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study fiercepharma
June 07, 2018
Roche’s multiple sclerosis newcomer Ocrevus was approved by the FDA last March bearing a warning about immunization.
EMA recommends approval of Roche's Ocrevus in relapsing forms of multiple sclerosis pharmafile
November 14, 2017
Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products for Human Use (CHMP) in the treatment of active relapsing forms of multiple sclerosis.
Roche chalks up Swiss approval for multiple sclerosis drug Ocrevus pharmafile
September 29, 2017
Roche has announced that its drug Ocrevus (ocrelizumab) has received marketing approval in Switzerland for the treatment of active relapsing forms of multiple sclerosis (RMS) as well as primary progressive forms of the disease
FDA Approves Ocrevus drugs
March 29, 2017
Genentech announced that the U.S. Food and Drug Administration (FDA) approved Ocrevus (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.

Previous page 1 2 Next page